Related references
Note: Only part of the references are listed.A Big Bang model of human colorectal tumor growth
Andrea Sottoriva et al.
NATURE GENETICS (2015)
Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status
Tao Wang et al.
HUMAN PATHOLOGY (2014)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Wedad M. Hanna et al.
MODERN PATHOLOGY (2014)
Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas
Eun Yoon Cho et al.
MODERN PATHOLOGY (2013)
Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors
Iman H. Hewedi et al.
DIAGNOSTIC PATHOLOGY (2012)
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
Akira Sawaki et al.
GASTRIC CANCER (2012)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Hyesil Seol et al.
MODERN PATHOLOGY (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
Laurent Arnouldi et al.
MODERN PATHOLOGY (2012)
Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
Shinichiro Kiyose et al.
PATHOLOGY INTERNATIONAL (2012)
Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma
Yan Song et al.
Chinese Journal of Cancer (2012)
Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations Time for a New Look at How to Report Heterogeneity
Kimberly H. Allison et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a Clinically Relevant Definition
Alastair I. Bartlett et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method
Elena Garcia-Garcia et al.
HISTOPATHOLOGY (2011)
Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
Stephen Lee et al.
HISTOPATHOLOGY (2011)
Dual-colour HER2/Chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples
Benedict Yan et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
HER2 genetic heterogeneity in breast carcinoma
Christian Oehlschlegel et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients
Kentaro Tamaki et al.
CANCER SCIENCE (2010)
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
M. Arnedos et al.
ANNALS OF ONCOLOGY (2009)
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
J. D. Barros-Silva et al.
BRITISH JOURNAL OF CANCER (2009)
HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
Robert E. Roses et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer
Anna Sutela et al.
ACTA ONCOLOGICA (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases
Mamatha Chivukula et al.
MODERN PATHOLOGY (2008)
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
Alfredo Santinelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction
Min A. Kim et al.
HUMAN PATHOLOGY (2007)
HER-2/neu amplification is an independent prognostic factor in gastric cancer
Dong Il Park et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma - From the Danish MALOVA ovarian cancer study
EVS Hogdall et al.
CANCER (2003)
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
DH Yu et al.
ONCOGENE (2000)
Share Paper
